Immatics Announces Full Year 2022 Financial Results and Corporate Update
Retrieved on:
Tuesday, March 21, 2023
GMP, Investment, Cohort, Head, Oncology, European Society for Medical Oncology, PRAME, Development, Patient, Corr, Congress, University, Half-life, Gene editing, Uveal melanoma, Research, Spanish mythology, CD8, Wellington Management Company, Entrepreneurship, CD4, IND, Conference, Safety, GSK, European Central Bank, ESMO, Central bank, COL6A3, TCR, Traction, Administration, Science Translational Medicine, Medical sociology, Ovarian cancer, Family, Synovial sarcoma, CRISPR, Doctor of Philosophy, Clinical trial, Bristol Myers Squibb, EUR, State Administrative Expenses, Toxic shock syndrome toxin-1, Bank, LP, Tumor microenvironment, VI, Peptide, Nivolumab, Pharmaceutical industry, Cryptocurrency, Vaccine, Medical imaging
In October 2022, Immatics provided an interim update on the ongoing IMA203 TCR-T monotherapy trial covering data from 27 patients in the completed Phase 1a dose escalation and the first 5 patients in the Phase 1b dose expansion trial.
Key Points:
- In October 2022, Immatics provided an interim update on the ongoing IMA203 TCR-T monotherapy trial covering data from 27 patients in the completed Phase 1a dose escalation and the first 5 patients in the Phase 1b dose expansion trial.
- This allows Immatics to shorten the turnaround time and to provide the cell therapy product candidate to patients faster.
- In October 2022, GSK provided Immatics with notice of its decision to terminate their collaboration.
- Immatics successfully completed an underwritten public offering in October 2022, raising approximately $110 million before deducting underwriting discount and offering expenses.